Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00160
2008-03-31
Prospective
N/A
Department of Paediatrics, CUHK
Department of Paediatrics, CUHK
N/A
Not Applicable
Lam, Hugh Simon Hung San
Department of Paediatrics, 6/F Clinical Sciences Building, PWH
35052211
hshslam@cuhk.edu.hk
The Chinese University of Hong Kong
Hong Kong, China
Lam, Hugh Simon Hung San
Department of Paediatrics, 6/F Clinical Sciences Building, PWH
35052211
hshslam@cuhk.edu.hk
The Chinese University of Hong Kong
Hong Kong, China
A randomized, double-blind, controlled study of Omegaven for prophylaxis against parenteral nutrition-associated cholestasis (PNAC) in infants requiring prolonged parenteral nutrition
A randomized, double-blind, controlled study of Omegaven for prophylaxis against parenteral nutrition-associated cholestasis (PNAC) in infants requiring prolonged parenteral nutrition
探討魚油(Omegaven)預防腸道外營養導致肝損傷的效果
Prevention of PNAC by omegaven
Hong Kong SAR, China
Yes
2008-02-06
Joint CUHK-NTEC Clinical Research Ethics Committee
CRE-2007.462-T
Parenteral nutrition-associated cholestasis (PNAC)
Other
parenteral lipid supplement
Omegaven (fish oil-based parenteral lipid supplement)
10% Omegaven
1.5 g/kg/day
For as long as subject requires parenteral nutrition (may be 4 months or more)
continuous intravenous infusion
Intralipid (soy-based parenteral lipid supplement)
10% Intralipid
1.5 g/kg/day
For as long as subject requires parenteral nutrition (may be 4 months or more)
continuous intravenous infusion
Inclusion criteria: (i) newborn infants without PNAC at the time of randomization; (ii) anatomical/functional short bowel syndrome or expected to be nil by mouth for > 4 weeks; (iii) informed parenteral consent
Exclusion criteria: (i) major congenital or lethal chromosomal abnormalities; (ii) multiorgan failure and imminent death; (iii) cholestatic jaundice secondary to known cause other than parenteral nutrition associated cholestasis (PNAC).
0 days
12 months
Both Male and Female
Interventional
Randomized
Randomised controlled trial
Active
Double-blind
Parallel
3
2008-04-30
26
Recruiting
Development of PNAC over 4 months
Infant growth; blood lipid profile; coagulation status; episodes of late-onset infection over 4 months.
2020-04-26
ChiCTR-TRC-08000717
2010-05-04
|
|
|
|
---|---|---|---|
No documents yet. |